Neonatal treatment with clomipramine induces behavioral alterations during adulthood that resemble symptoms observed in human depression. Therefore, it has been proposed as an animal model of depression. Impairment of male sexual performance is one of the main effects of this treatment. Using this model of depression, we evaluated the effects of drugs that stimulate sexual performance by acting selectively on the adrenergic, serotonergic, or cholinergic system. Yohimbine, a selective antagonist of the alpha-2 receptors; 8-OH-DPAT, a selective agonist of the 5-HT1A receptors; and oxotremorine, a muscarinic agonist, were administered to male rats neonatally treated with clomipramine that showed sexual behavior impairments. Yohimbine and oxotremorine induced only a slight improvement of sexual deficiencies. 8-OH-DPAT not only restored sexual behavior to normal levels, but induced facilitation in most of the copulatory parameters. These results suggest that neonatal treatment with clomipramine induces sexual deficits acting mainly on the adrenergic and cholinergic systems, while the serotoninergic system seems to be preserved.